Does dihexa increase cancer risk through HGF/c-Met activation?

The short answer

Dihexa works by activating the HGF/c-Met pathway — and that same pathway is one of the most well-characterized cancer-driving (oncogenic) systems in human biology. That doesn't prove dihexa causes cancer, but it's a legitimate theoretical concern that has never been resolved: no carcinogenicity or tumor-promotion studies have been done on dihexa in any species. The honest verdict is "unknown risk with a plausible mechanism," and that's reason for real caution — especially for anyone with cancer in their history.

Evidence tier: Tier 1–2 for c-Met being an oncogenic pathway; Tier 3 (theoretical) for the dihexa-specific cancer risk, because no safety data exists. Educational content, not medical advice.

The key points:

• Dihexa is an HGF/c-Met activator — that's how it drives synaptogenesis
• c-Met is a validated oncogene — approved cancer drugs work by blocking it
• No cancer-safety data on dihexa exists — the risk is untested, not disproven
• Highest concern for anyone with a cancer history or precancerous cells

For what dihexa is and its cognitive claims, see our dihexa page.

How does dihexa work, and why is c-Met a cancer concern?

Evidence tier: 1–2 — the pathway biology is well established.

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a metabolically stabilized analog of Angiotensin IV, designed to cross the blood-brain barrier and promote the formation of new synapses. Its mechanism is the crux of the safety question: dihexa acts as a hepatocyte growth factor (HGF) mimetic, binding HGF and potentiating signaling through the c-Met receptor, which drives the spinogenesis and synaptogenesis behind its pro-cognitive claims (Benoist 2014; McCoy 2013). In the brain, that c-Met activation is the point.

The problem is what c-Met activation does elsewhere. The HGF/c-Met axis is one of the most studied oncogenic pathways in cancer biology: c-Met activation promotes cell proliferation, survival, motility, invasion, and angiogenesis — the exact hallmarks of tumor growth and metastasis — and HGF/c-Met dysregulation is implicated in lung, liver, gastric, breast, and other cancers (Comoglio 2018, *Nature Reviews Cancer*). The clinical world treats this pathway as a target to shut down: FDA-approved cancer drugs like capmatinib and tepotinib are c-Met inhibitors. Dihexa does the biochemical opposite — it's a c-Met agonist. That inversion is why the cancer question is unavoidable rather than alarmist.

Does dihexa actually cause cancer?

Evidence tier: 3 — no evidence either way; this is the honest gap.

Here's the careful answer: there is no evidence that dihexa causes cancer, and no evidence that it's safe — because the studies that would tell us have never been done. No long-term carcinogenicity, tumorigenicity, genotoxicity, or chronic-toxicology data has been published for dihexa in any species. A systemically active, blood-brain-barrier-penetrating c-Met agonist has simply never been tested in humans for tumor-promoting effects. So anyone claiming dihexa is "proven safe" or "proven to cause cancer" is overstating what's known.

What we can reason from mechanism is this: the intent is brain-targeted synaptogenesis, but dihexa is systemically administered, and a c-Met agonist that reaches the rest of the body could, in principle, promote proliferation or invasion in any tumor or precancerous cell population that's already present — even one a person doesn't know about. It wouldn't necessarily initiate cancer from nothing, but the bigger theoretical concern is promotion: feeding a growth signal to cells primed to respond. Whether that happens at the doses people use, and how much systemic c-Met activation actually occurs, is genuinely unknown. The mechanistic plausibility is high; the real-world magnitude is unmeasured. That combination — plausible mechanism, zero safety data — is precisely the situation that warrants caution rather than reassurance.

Doesn't dihexa target the brain — so why worry about the body?

Evidence tier: 3 — the targeting argument is real but incomplete.

This is the most common counterargument, and it has a kernel of truth that doesn't fully hold up. Dihexa was designed for brain penetration — that's its selling point, and proponents argue the cognitive dose is aimed at central synaptogenesis, not systemic c-Met activation. But "crosses the blood-brain barrier well" is not the same as "stays out of the rest of the body." A systemically administered compound circulates everywhere before and while it reaches the brain, so peripheral tissues — including any organ harboring a precancerous lesion — are exposed to the c-Met-activating signal too. Brain-targeting improves the ratio; it doesn't create a force field around the rest of you.

The honest problem is that the actual degree of systemic c-Met activation at cognitive doses has never been measured in humans, so the "it's brain-only" reassurance rests on assumption rather than data. There's also the question of duration and accumulation: even modest peripheral exposure, repeated over months, is a different risk profile than a single dose — and again, no one has studied it. So while the targeting argument legitimately reduces the theoretical concern compared to a non-CNS-selective c-Met agonist, it doesn't eliminate it, and it can't be used to declare dihexa safe. The gap between "designed to favor the brain" and "proven not to promote tumors anywhere" is exactly the gap that the missing safety studies would fill.

Who should be especially cautious with dihexa?

Evidence tier: 2–3 — reasoned from the pathway and absent data.

If the mechanism gives anyone pause, it should be people whose biology is already primed for the concern. That includes anyone with a personal history of cancer, a strong family history, known precancerous conditions or unexplained growths, or who is otherwise at elevated cancer risk — for them, deliberately activating a major oncogenic pathway is a hard-to-justify gamble given the absence of data. It's also worth flagging that some of dihexa's foundational efficacy claims have faced data-integrity questions, so the cognitive upside is less certain than marketing implies, which shifts the risk-benefit further toward caution.

More broadly, dihexa is an unapproved research compound with no human safety program, almost always sourced from the gray market with the usual purity and dosing uncertainties on top of the mechanistic concern — see our safety and sourcing guide. None of this means everyone who has used dihexa will develop cancer; brief exposures may well carry low absolute risk. But "we don't know, and the mechanism points the wrong way" is a fundamentally different safety position from the well-tolerated profile of many other peptides, and people deserve to weigh it honestly. For the broader cognitive-peptide landscape and better-studied alternatives, see peptides for cognitive performance.

What's the honest risk verdict?

Evidence tier: 3 — synthesis of mechanism + missing data.

Pulling it together: dihexa should be classified as carrying a high degree of unknown risk specifically on the cancer question. The pathway it activates is unambiguously oncogenic (Tier 1 science); the dihexa-specific tumor risk is untested (no data); and the compound is unapproved and self-sourced. That's three independent reasons for caution stacking on top of each other. The reasonable framing isn't fear-mongering ("dihexa causes cancer" — unproven) or dismissal ("no evidence of harm, so it's fine" — misleading, since absence of studies isn't absence of risk). It's: a biologically plausible, unquantified cancer-promotion risk that you cannot currently rule out.

For someone weighing dihexa, that means the bar should be high, the use case compelling, the duration limited, and the decision made with a clinician — and for anyone with cancer risk factors, the sensible answer is to avoid it until real safety data exists. The cognitive benefits, even if real, don't obviously outweigh activating an oncogenic pathway blind.

Limitations

This is educational content, not medical advice.

• No carcinogenicity or chronic-toxicity data exists for dihexa — the cancer risk is untested, not disproven.
• c-Met is a validated oncogenic pathway — approved cancer drugs inhibit it; dihexa activates it.
• Highest concern for those with cancer history/risk — avoid pending real data.
• Dihexa is unapproved and gray-market — sourcing and dosing add further uncertainty.
• Some efficacy claims face data-integrity questions — the upside is less certain than marketed.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Dihexa's cancer question comes straight from its mechanism: it activates HGF/c-Met, one of the best-characterized oncogenic pathways in human biology — the very pathway that approved cancer drugs are designed to block. That makes a tumor-promotion concern biologically plausible. But no carcinogenicity, tumorigenicity, or chronic-safety studies have ever been done on dihexa, so the actual risk is unmeasured, not disproven. The honest verdict is high unknown risk: don't panic over past brief use, but treat dihexa as a compound that could feed an existing or precancerous cell population, keep any use limited and clinician-guided, and avoid it entirely if you have personal or family cancer risk — until real safety data exists.

Related on this site

• Dihexa: overview and cognitive claims
• Peptides for cognitive performance: what's backed by evidence
• Peptide safety and sourcing guide
• Our evidence-tier framework

References

• Comoglio PM, Trusolino L, Boccaccio C. 2018. Known and novel roles of the MET oncogene in cancer. Nature Reviews Cancer. PMID 29674709 — MET/c-Met as an oncogenic pathway.
• Benoist CC, et al. 2014. The procognitive and synaptogenic effects of angiotensin IV-derived peptides depend on HGF/c-Met activation. J Pharmacol Exp Ther. PMID 25187433 — dihexa's HGF/c-Met mechanism.
• McCoy AT, et al. 2013. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. PMID 23055539 — dihexa design and HGF binding.